Open the mobile version, with barcode scanning
Class II Ongoing

DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx.

Why: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Company
Direct Rx
Dawsonville, GA, United States
Reported
Jul 1, 2026
Recall started
Jun 22, 2026
Where sold
U.S. Nationwide
Amount
263 Bottles
Full product description
DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx.
Lots / codes affected
Lot: a) 09JA2530, 31JA2507, expires: 04/30/2027; b) Lot: 09DE2412, 09JA2528, 29JA2511, expires: 04/30/2027.

Class I: could cause serious harm or death. Class II: could cause temporary or treatable problems. Class III: unlikely to cause harm.